• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exelixis Inc (NQ: EXEL )

    22.96 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 300
    Open 22.96
    Bid (Size) 22.35 (1)
    Ask (Size) 23.00 (11)
    Prev. Close 22.96
    Today's Range 22.96 - 22.96
    52wk Range 18.64 - 24.34
    Shares Outstanding 315,048,788
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
    From Exelixis, Inc.
    Via Business Wire
    In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
    EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
    Via Chartmill

    Performance

    YTD
    -4.05%
    -4.05%
    1 Month
    +3.14%
    +3.14%
    3 Month
    -2.42%
    -2.42%
    6 Month
    +3.94%
    +3.94%
    1 Year
    +15.84%
    +15.84%

    More News

    Read More
    7 Cheap Biotech Stocks With Major Upside Potential
    Via InvestorPlace
    When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
    Via Chartmill
    The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
    Via Benzinga
    Technical Signals Point to a Possible Breakout for EXELIXIS INC.
    Via Chartmill
    What Analysts Are Saying About Exelixis Stock
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
    From Exelixis, Inc.
    Via Business Wire
    Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
    From Exelixis, Inc.
    Via Business Wire
    In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
    Via The Motley Fool
    MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
    Via Benzinga
    Just Say No to Drugs: 3 Pharma Stocks to Avoid
    Via InvestorPlace
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
    From Exelixis, Inc.
    Via Business Wire
    Exelixis (EXEL) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
    From Exelixis, Inc.
    Via Business Wire
    The Top 3 Biotech Stocks to Buy in April 2024
    Via InvestorPlace
    NASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
    From Exelixis, Inc.
    Via Business Wire
    NASDAQ:EXEL is an undervalued gem with solid fundamentals.
    Via Chartmill
    3 Biotech Stocks to Buy on the Dip: March 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.